HK1202870A1 - Improved modulators of hec1 activity and methods therefor hec1 - Google Patents

Improved modulators of hec1 activity and methods therefor hec1

Info

Publication number
HK1202870A1
HK1202870A1 HK15103447.6A HK15103447A HK1202870A1 HK 1202870 A1 HK1202870 A1 HK 1202870A1 HK 15103447 A HK15103447 A HK 15103447A HK 1202870 A1 HK1202870 A1 HK 1202870A1
Authority
HK
Hong Kong
Prior art keywords
hec1
activity
methods therefor
improved modulators
modulators
Prior art date
Application number
HK15103447.6A
Other languages
English (en)
Chinese (zh)
Inventor
Yu-Ling Huang
Shih-Hsien Chuang
Ying-Shuan Eda Lee
Jiann-Jyh Huang
Johnson Lau
Original Assignee
Taivex Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taivex Therapeutics Corp filed Critical Taivex Therapeutics Corp
Publication of HK1202870A1 publication Critical patent/HK1202870A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
HK15103447.6A 2011-11-29 2015-04-22 Improved modulators of hec1 activity and methods therefor hec1 HK1202870A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161564773P 2011-11-29 2011-11-29
PCT/US2012/067132 WO2013082324A1 (en) 2011-11-29 2012-11-29 Improved modulators of hec1 activity and methods therefor

Publications (1)

Publication Number Publication Date
HK1202870A1 true HK1202870A1 (en) 2015-10-09

Family

ID=48536070

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15103447.6A HK1202870A1 (en) 2011-11-29 2015-04-22 Improved modulators of hec1 activity and methods therefor hec1

Country Status (12)

Country Link
US (2) US8999983B2 (ja)
EP (1) EP2785714B1 (ja)
JP (1) JP5970554B2 (ja)
KR (1) KR101983585B1 (ja)
CN (1) CN104254534B (ja)
AU (1) AU2012345843B2 (ja)
ES (1) ES2712134T3 (ja)
HK (1) HK1202870A1 (ja)
MX (1) MX371378B (ja)
SG (1) SG11201402144WA (ja)
TW (1) TWI640519B (ja)
WO (1) WO2013082324A1 (ja)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11071736B2 (en) * 2011-11-21 2021-07-27 Taivex Therapeutics Corporation Modulators of HEC1 activity and methods therefor
AU2013326600B2 (en) 2012-10-02 2017-03-30 Bayer Cropscience Ag Heterocyclic compounds as pesticides
AU2014347026A1 (en) * 2013-11-06 2016-06-23 Bristol-Myers Squibb Company Substituted pyridine derivatives useful as GSK-3 inhibitors
AU2015264422A1 (en) * 2014-05-17 2016-11-17 The Regents Of The University Of California Centromere/kinetochore protein genes for cancer diagnosis, prognosis and treatment selection
WO2019169135A1 (en) 2018-02-28 2019-09-06 University Of Southern California Compositions and methods for modulating inflammatory and degenerative disorder
TWI750905B (zh) * 2020-11-19 2021-12-21 財團法人國家衛生研究院 噻唑化合物作為蛋白質激酶抑制劑

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0228175A (ja) * 1987-12-14 1990-01-30 Sawai Seiyaku Kk チアゾール環およびテトラゾール環を有するカルボキシアミド誘導体およびその用途
US6043246A (en) * 1996-12-03 2000-03-28 Banyu Pharmaceutical Co., Ltd. Urea derivatives
CA2380206A1 (en) * 1999-07-26 2001-02-01 Shionogi & Co., Ltd. Pharmaceutical compositions exhibiting thrombopoietin receptor agonism
WO2001030764A1 (fr) * 1999-10-22 2001-05-03 Takeda Chemical Industries, Ltd. Alcools de phenyl-1-(1h-imidazol-4-yl) substitues en position 1, procede de preparation et utilisation de ces derniers
EP1519736A2 (en) 2002-06-12 2005-04-06 Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E.V. Use of hec1 antagonists in the treatment of proliferative disorders and cancer
US8252520B2 (en) 2002-10-11 2012-08-28 Taivex Therapeutics Corporation Methods and compounds for inhibiting Hec1 activity for the treatment of proliferative diseases
RU2006111093A (ru) 2003-09-06 2007-10-27 Вертекс Фармасьютикалз Инкорпорейтед (Us) Модуляторы атр-связывающих кассетных транспортеров
EP1679309A4 (en) * 2003-10-24 2007-03-28 Ono Pharmaceutical Co ANTISTRESS MEDICAMENT AND ITS MEDICAL USE
WO2005040161A1 (en) * 2003-10-27 2005-05-06 S*Bio Pte Ltd Biaryl linked hydroxamates: preparation and pharmaceutical applications
BRPI0507278A (pt) * 2004-01-30 2007-06-26 Vertex Pharma moduladores dos transportadores do cassete de ligação ao atp
WO2006136823A1 (en) * 2005-06-21 2006-12-28 Astex Therapeutics Limited Heterocyclic containing amines as kinase b inhibitors
WO2007004038A1 (en) 2005-07-05 2007-01-11 Pfizer Products Inc. Aminothiazole derivatives as agonists of the thrombopoietin receptor
WO2007008541A2 (en) * 2005-07-08 2007-01-18 Kalypsys, Inc. Cellular cholesterol absorption modifiers
ES2439736T3 (es) * 2005-11-08 2014-01-24 Vertex Pharmaceuticals Incorporated Moduladores heterocíclicos de transportadores de casete de unión a ATP
CN101331125A (zh) * 2005-12-12 2008-12-24 健亚生物科技公司 N-(5-元杂芳香环)-酰胺基抗病毒化合物
WO2007131071A2 (en) 2006-05-02 2007-11-15 Washington State University Mig-7 as a specific anticancer target
US20090181952A1 (en) * 2008-01-14 2009-07-16 Wyeth Compounds useful as alpha7 nicotinic acetylcholine receptor agonists
US20120108614A1 (en) * 2008-05-14 2012-05-03 Chong Jayhong A Compounds and compositions for treating chemical warfare agent-induced injuries
WO2009144548A1 (en) * 2008-05-28 2009-12-03 Glenmark Pharmaceuticals S.A. Imidazo [2,1-b] purine derivatives as trpa1 modulators
US20120046305A1 (en) * 2008-09-24 2012-02-23 Moran Magdalene M Methods and compositions for treating respiratory disorders
US8324385B2 (en) 2008-10-30 2012-12-04 Madrigal Pharmaceuticals, Inc. Diacylglycerol acyltransferase inhibitors
ES2424340T3 (es) * 2009-03-23 2013-10-01 Glenmark Pharmaceuticals S.A. Derivados de isotiazolo-pirimidindiona como moduladores de TRPA1
DE102009014484A1 (de) * 2009-03-23 2010-09-30 Bayer Schering Pharma Aktiengesellschaft Substituierte Piperidine
EP2309273B1 (en) 2009-09-16 2016-05-18 ZEILLINGER, Robert Novel tumor marker determination
CN103038231B (zh) 2010-03-17 2016-04-20 泰纬生命科技股份有限公司 Hec1活性调节剂及其方法
CN104395752B (zh) * 2011-11-21 2017-09-15 泰纬生命科技股份有限公司 对hec1活性调节剂具有反应的癌症的生物标记

Also Published As

Publication number Publication date
ES2712134T3 (es) 2019-05-09
US20130190312A1 (en) 2013-07-25
JP2014534271A (ja) 2014-12-18
WO2013082324A1 (en) 2013-06-06
AU2012345843B2 (en) 2017-11-23
US8999983B2 (en) 2015-04-07
EP2785714A4 (en) 2015-09-09
TW201326164A (zh) 2013-07-01
EP2785714B1 (en) 2018-11-21
CN104254534B (zh) 2017-07-14
KR20140138596A (ko) 2014-12-04
MX2014006157A (es) 2015-04-08
CN104254534A (zh) 2014-12-31
JP5970554B2 (ja) 2016-08-17
EP2785714A1 (en) 2014-10-08
NZ624552A (en) 2015-06-26
AU2012345843A1 (en) 2014-05-29
KR101983585B1 (ko) 2019-05-29
US10588909B2 (en) 2020-03-17
US20150250794A1 (en) 2015-09-10
MX371378B (es) 2020-01-28
TWI640519B (zh) 2018-11-11
SG11201402144WA (en) 2014-09-26

Similar Documents

Publication Publication Date Title
IL263020A (en) New modulators and methods of use
IL247595A0 (en) New modulators and methods of use
HK1215284A1 (zh) 位點特異性酶和使用方法
HK1176055A1 (zh) 活動的調製器及其調製方法
GB2488674B (en) Catalyst and method of preparation
EP2672820A4 (en) MANNOSID COMPOUNDS AND METHOD OF USE THEREOF
IL227333A0 (en) A method for preparing lycosphingolipids and their uses
SG10201601792UA (en) Novel modulators and methods of use
ZA201401653B (en) Pyrazol-4yl-heterocyclyl-carboxamide compounds and methods of use
SG10201506782XA (en) Notum protein modulators and methods of use
EP2665486A4 (en) COMPOSITIONS AND METHODS OF MODULATING ACTIVITY OF GAMMA-C CYTOKINES
HK1202870A1 (en) Improved modulators of hec1 activity and methods therefor hec1
EP2852397A4 (en) HUWENTOXIN IV VARIANTS AND METHODS OF USE
EP2726218A4 (en) ADHESIVE COMPLEX COACERVATES AND METHODS OF MAKING AND USING SAME
EP2763962A4 (en) METHOD FOR TREATMENT WITH SIRT2 MODULATORS
EP2709999A4 (en) QUINAZOLINE-7-ETHER COMPOUNDS AND METHODS OF USE
EP2670245A4 (en) ALPHA-CÉTOHÉTÉROCYCLES AND METHODS OF MAKING AND USING THEM
EP2753359A4 (en) SERPINF2 BINDEMOLEKÜLE AND METHOD FOR THEIR USE
AP2013007019A0 (en) Gaming system and method of use
EP2782670A4 (en) COPPER ZIRCONIUM CATALYST AND METHOD FOR ITS USE AND MANUFACTURE
EP2898044A4 (en) SOLID HYDROGEL MEDIA AND METHOD FOR THE PRODUCTION AND USE THEREOF
EP2691420A4 (en) MODULATORS OF B2 PLEXINE ACTIVITY
GB2516380B (en) Catalyst and method of preparation
GB201316230D0 (en) Catalysts and methods of making and using catalysts
AU2011901049A0 (en) Catalysts and Methods of Use